Trials / Recruiting
RecruitingNCT06246968
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Does Cryoablation Boost Immune Response Improving the Benefits of Pembrolizumab in Patients With Metastatic or Locally Advanced Triple Negative Breast Cancer?
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with cryoablation OR pembrolizumab alone. Participants will be randomly assigned.
Conditions
- Metastatic Breast Cancer
- Breast Cancer
- Breast Cancer Stage IV
- Triple Negative Breast Cancer
- Triple Negative Breast Neoplasms
- Metastatic Triple-Negative Breast Carcinoma
- Locally Advanced Breast Cancer
- Locally Advanced Triple-Negative Breast Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | Participants will receive Pembrolizumab as part of standard of care treatment. |
| DEVICE | Cryoablation | Cryoablation is a type of thermal ablation that is a minimally invasive alternative technique to surgical resection. |
Timeline
- Start date
- 2024-01-29
- Primary completion
- 2027-01-29
- Completion
- 2027-01-29
- First posted
- 2024-02-07
- Last updated
- 2025-05-21
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06246968. Inclusion in this directory is not an endorsement.